Hematological oncology · 2012
T-cell acute lymphoblastic leukaemia after liver transplantation: post-transplant lymphoproliferative disorder or coincidental de novo leukaemia?
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fang Yanan, Pinkney Kerice A, Lee John C, Gindin Tatyana, Weiner Michael A, Alobeid Bachir, Bhagat Govind
Аннотация
Post-transplant lymphoproliferative disorders of T-cell origin are quite uncommon, and the vast majority represent neoplasms of mature, post-thymic T- or natural killer cells. Here, we report a rare case of T-cell acute lymphoblastic leukaemia (T-ALL), which occurred in an 18-year-old man who had undergone three liver transplants, initially for biliary atresia and subsequently for graft failure due to chronic rejection. He had received immunosuppression with cyclosporine and tacrolimus, as well as short-term treatment with OKT3. The T-ALL occurred 16 years after the first liver transplant. This case highlights the challenge for classifying rare neoplasms occurring in recipients of solid organ transplants that are currently not recognized to lie within the spectrum of post-transplant lymphoproliferative disorders. Given the long interval between the liver transplants and the development of T-ALL, a coincidental occurrence of the leukaemia cannot be ruled out. However, the potential roles of immunosuppressive therapy and other co-morbid conditions of the individual as possible risk factors for the pathogenesis of T-ALL are discussed.
Предметные рубрики MeSH
AdolescentBiliary AtresiaCausalityClone CellsComorbidityCyclosporineDiagnosis, DifferentialDisease SusceptibilityGene Rearrangement, beta-Chain T-Cell Antigen ReceptorGraft RejectionHumansImmunocompromised HostImmunosuppressive AgentsLeukemia, Radiation-InducedLiver TransplantationLymphoproliferative DisordersMaleMuromonab-CD3Postoperative ComplicationsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaRadiographyRemission InductionReoperationTacrolimusTime Factors